News
HanchorBio Presents Two Oral Presentations at ESMO TAT Asia 2026 Highlighting Progress Across Its Next-Generation Immunotherapy Pipeline
HanchorBio announced that two company-sponsored clinical programs were featured in oral presentations at the European Society for Medical Oncology Targeted Anticancer Therapies Asia Congress 2026, ESMO TAT Asia 2026, held in Hong Kong.
Jun 13, 2026
Read more
HanchorBio Presents Late-Breaking Data at FOCIS 2026 Supporting Innate-Immune Product Engine Across Oncology and Autoimmune Disease
HanchorBio announced the presentation of late-breaking clinical and translational data at the Federation of Clinical Immunology Societies Annual Meeting, FOCIS 2026, being held June 9-12, 2026, in San Francisco.
Jun 10, 2026
Read more
HanchorBio Presents Two ASCO 2026 Abstracts Highlighting HCB101 Combination Activity and HCB301 First-in-Human Clinical Progress
HanchorBio announced updated clinical data for HCB101 and HCB301 presented at the 2026 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.
Jun 01, 2026
Read more
HanchorBio to Hold May 11 Investor Presentation Ahead of Planned Taiwan Innovation Board Listing
HanchorBio announced that it will hold an investor presentation on May 11 ahead of its planned listing on the Taiwan Innovation Board later this month.
May 08, 2026
Read more
HanchorBio Highlights Next Generation Combination Backbone Potential, Platform Expansion Beyond Oncology, and Tri-specific Mechanistic Progress at TJCC 2026
HanchorBio presented at the 30th Taiwan Joint Cancer Conference (TJCC 2026). Across a keynote lecture and the company symposium, HanchorBio highlighted clinical and translational data supporting HCB101 as a clinically versatile innate immune backbone and presented a working mechanism framework for its next-generation tri-specific program, HCB301.
May 04, 2026
Read more
HanchorBio Presents Early Frontline Triple-Negative Breast Cancer Data for HCB101 Combination at GBCC 2026
HanchorBio announced the first dedicated presentation of HCB101 clinical data from an ongoing study evaluating HCB101 in combination with anti-PD-1 and nab-paclitaxel in patients with advanced triple-negative breast cancer (TNBC) at the Global Breast Cancer Conference 2026 (GBCC 2026) in Seoul, Korea.
Apr 23, 2026
Read more
HanchorBio Reports Strong H1 2026 Scientific Communication Momentum and Highlights Upcoming Q2 Conference Participation
HanchorBio announced strong scientific communication momentum in the first half of 2026, marked by a broad series of oral, mini-oral, symposium, keynote, and poster presentations across major international scientific meetings. The Company also highlighted its upcoming and recently accepted conference participation in Q2 2026, underscoring continued external visibility across multiple programs, disease areas, and translational settings.
Apr 20, 2026
Read more
HanchorBio Invited to Participate in the 19th QIC CEO Week
HanchorBio has been invited to participate in the 19th QIC CEO Week to meet with international institutional investors in Singapore to share corporate progress and strategic priorities.
Apr 13, 2026
Read more
HanchorBio Presents at WIC-APAC 2026: The CD47 Field Enters a New Design Era
HanchorBio participated in the World Immunotherapy Council Asia-Pacific Conference (WIC-APAC 2026), to be held on March 29, 2026, at the International Convention Center, Chang Yung-Fa Foundation, Taipei, Taiwan. At the conference, Alvin Luk, PhD, MBA, CCRA, President & Chief Medical Officer (CMO) of HanchorBio (Group), and CEO of HanchorBio US, was invited to present his clinical perspectives on CD47–SIRPα in cancer immunotherapy, as well as the latest trends in next-generation multi-checkpoint engineering.
Mar 30, 2026
Read more
HanchorBio Presents First Dedicated HCB101 Head and Neck Cancer Data in Oral Presentation at ICHNO 2026
HanchorBio announced the first dedicated presentation of HCB101 clinical data in head and neck squamous cell carcinoma (HNSCC) in an oral presentation at ICHNO 2026 (the 10th International Congress on Innovative Approaches in Head and Neck Oncology), a joint ESTRO, EHNS, and ESMO congress, in Seville, Spain.
Mar 20, 2026
Read more